Santa Monica cancer drug developer Kite Pharma Inc. announced it had entered into another exclusive worldwide license with the National Institutes of Health for immuno-oncology drug candidates. This latest license covers treatments targeting tumors associated with lung, gastric, pancreatic and breast cancer, among others.

The NIH’s National Cancer Institute, under a cooperative research and development agreement with Kite, is conducting two clinical trials of candidates for t-cell drugs that would target melanoma-associated antigens.

As part of the licensing agreement, Kite Pharma will give the NIH an upfront payment and royalties on net product sales as well as sales, clinical and regulatory milestone payments.

Kite shares closed the day down 1 percent, to $67.07.